Research & Literature

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

Broder MS, Beenhouwer D, Strosberg JR, et al.

World journal of gastroenterology 2015; (21(6)):1945-55 doi:10.3748/wjg.v21.i6.1945.

Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms.

Boutzios G, Kaltsas G

Frontiers of hormone research 2015; (44()):40-57 doi:10.1159/000382053.

Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor.

Bouma G, van Faassen M, Kats-Ugurlu G, et al.

Neuroendocrinology 2016; (103(5)):489-94 doi:10.1159/000440621.

Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.

Adaway JE, Dobson R, Walsh J, et al.

Annals of clinical biochemistry 2016; (53(Pt 5)):554-60 doi:10.1177/0004563215613109.

Surgical Treatment of Small Bowel Neuroendocrine Tumors.

Farley HA, Pommier RF

Hematology/oncology clinics of North America 2016; (30(1)):49-61.

Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia.

Maasberg S, Knappe-Drzikova B, Vonderbeck D, et al.

Neuroendocrinology 2017; (104(1)):11-25 doi:10.1159/000442983.

Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.

Pericleous M, Caplin ME, Tsochatzis E, et al.

Asia-Pacific journal of clinical oncology 2016; (12(1)):61-9 doi:10.1111/ajco.12438.

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Pokuri VK, Fong MK, Iyer R

Current oncology reports 2016; (18(1)):7 doi:10.1007/s11912-015-0492-7.

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik AI, Wolin EM, Liyanage N, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2016; (22(9)):1068-80 doi:10.4158/EP151172.OR.

Flushing in (neuro)endocrinology.

Hannah-Shmouni F, Stratakis CA, Koch CA

Reviews in endocrine & metabolic disorders 2016; (17(3)):373-380 doi:10.1007/s11154-016-9394-8.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Kulke MH, Hörsch D, Caplin ME, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(1)):14-23 doi:10.1200/JCO.2016.69.2780.

The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.

Barrio M, Czernin J, Fanti S, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(5)):756-761 doi:10.2967/jnumed.116.185587.

Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements.

Tirosh A, Papadakis GZ, Millo C, et al.

European journal of endocrinology 2017; (176(5)):575-582.

Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.

Rodríguez Laval V, Pavel M, Steffen IG, et al.

Neuroendocrinology 2018; (106(2)):139-147 doi:10.1159/000474941.

Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.

Borna RM, Jahr JS, Kmiecik S, et al.

Anesthesiology clinics 2017; (35(2)):327-339 doi:10.1016/j.anclin.2017.01.021.

Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations.

Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J

Endocrine connections 2017; (6(6)):R87-R98 doi:10.1530/EC-17-0071.

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Bergsma H, van Lom K, Raaijmakers MHGP, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018; (59(3)):452-458 doi:10.2967/jnumed.117.189712.

A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis.

Forero Molina MA, Garcia E, Gonzalez-Devia D, et al.

The World Allergy Organization journal 2017; (10(1)):30 doi:10.1186/s40413-017-0161-4.

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

Fisher GA, Wolin EM, Liyanage N, et al.

The oncologist 2018; (23(1)):16-24 doi:10.1634/theoncologist.2017-0284.

Updates on the biology of serotonin and tryptophan hydroxylase.

Swami T, Weber HC

Current opinion in endocrinology, diabetes, and obesity 2018; (25(1)):12-21 doi:10.1097/MED.0000000000000383.

Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

Tapia Rico G, Li M, Pavlakis N, et al.

Cancer treatment reviews 2018; (66()):1-6 doi:10.1016/j.ctrv.2018.03.002.

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

Weickert MO, Kaltsas G, Hörsch D, et al.

Clinical therapeutics 2018; (40(6)):952-962.e2 doi:10.1016/j.clinthera.2018.04.006.

Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.

Lyseng-Williamson KA

Drugs 2018; (78(9)):941-950 doi:10.1007/s40265-018-0935-1.

Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.

Sanli Y, Garg I, Kandathil A, et al.

AJR. American journal of roentgenology 2018; (211(2)):267-277 doi:10.2214/AJR.18.19881.

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0296.

Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.

Kinney MAO, Nagorney DM, Clark DF, et al.

Journal of clinical anesthesia 2018; (51()):93-96 doi:10.1016/j.jclinane.2018.08.005.

Carcinoid Heart Disease: A Review.

Hayes AR, Davar J, Caplin ME

Endocrinology and metabolism clinics of North America 2018; (47(3)):671-682 doi:10.1016/j.ecl.2018.04.012.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(12)):1770-1786 doi:10.1038/s41379-018-0110-y.

ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.

Subramaniam RM, Bradshaw ML, Lewis K, et al.

Clinical nuclear medicine 2018; (43(12)):899-908 doi:10.1097/RLU.0000000000002309.

Management of carcinoid syndrome: a systematic review and meta-analysis.

Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW

Endocrine-related cancer 2019; (26(3)):R145-R156.

Nutritional and vitamin status in patients with neuroendocrine neoplasms.

Clement DS, Tesselaar ME, van Leerdam ME, et al.

World journal of gastroenterology 2019; (25(10)):1171-1184 doi:10.3748/wjg.v25.i10.1171.

Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study.

Uema D, Alves C, Mesquita M, et al.

Journal of clinical medicine 2019; (8(3)) doi:10.3390/jcm8030405.

Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.

Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR

Clinical lung cancer 2019; (20(3)):e376-e392 doi:10.1016/j.cllc.2019.02.007.

Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.

Kwon DH, Paciorek A, Mulvey CK, et al.

Pancreas 2019; (48(4)):496-503 doi:10.1097/MPA.0000000000001271.

Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.

Wolin EM, Benson Iii AB

Oncology 2019; (96(6)):273-289 doi:10.1159/000499049.

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.

Strosberg J, Joish VN, Giacalone S, et al.

The oncologist 2019; (24(11)):1446-1452 doi:10.1634/theoncologist.2018-0921.

Carcinoid Syndrome: Updates and Review of Current Therapy.

Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S

Current treatment options in oncology 2019; (20(9)):70 doi:10.1007/s11864-019-0671-0.

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Hennrich U, Kopka K

Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Laing E, Kiss N, Michael M, Krishnasamy M

Neuroendocrinology 2020; (110(5)):430-442 doi:10.1159/000503634.

Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?

Babazadeh NT, Schlund DJ, Cornelius T, et al.

World journal of surgery 2020; (44(2)):604-611 doi:10.1007/s00268-019-05216-3.

Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.

Huynh L, Cai B, Cheng M, et al.

Pancreas 2019; (48(9)):1126-1135 doi:10.1097/MPA.0000000000001403.

Carcinoid Heart Disease: a Comprehensive Review.

Hassan SA, Palaskas NL, Agha AM, et al.

Current cardiology reports 2019; (21(11)):140 doi:10.1007/s11886-019-1207-8.

CAN MICROWAVE ABLATION BE AN ALTERNATIVE TO RESECTION FOR THE TREATMENT OF NEUROENDOCRINE LIVER METASTASES?

Perrodin SF, Renzulli MM, Maurer MH, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(4)):378-387 doi:10.4158/EP-2019-0394.

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.

Dillon JS, Kulke MH, Hörsch D, et al.

Journal of gastrointestinal cancer 2021; (52(1)):212-221 doi:10.1007/s12029-020-00375-2.

Carcinoid Syndrome: A Review.

Gade AK, Olariu E, Douthit NT

Cureus 2020; (12(3)):e7186 doi:10.7759/cureus.7186.

Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome.

Clement D, Ramage J, Srirajaskanthan R

Journal of oncology 2020; (2020()):8341426 doi:10.1155/2020/8341426.

[Multimodal therapy improved carcinoid syndrome secondary to liver metastases of an atypical lung carcinoid tumor:a case report].

Shimizu T, Adikrisna R, Shimada K, et al.

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2020; (117(7)):635-645 doi:10.11405/nisshoshi.117.635.

Surgical Management of Primary Small Bowel NET Presenting Acutely with Obstruction or Perforation.

Rajaretnam NS, Meyer-Rochow GY,

World journal of surgery 2021; (45(1)):203-207 doi:10.1007/s00268-020-05689-7.

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors.

Pusceddu S, Rossi RE, Torchio M, et al.

Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082468.

Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

Khan MS, Walter T, Buchanan-Hughes A, et al.

World journal of gastroenterology 2020; (26(30)):4537-4556 doi:10.3748/wjg.v26.i30.4537.

Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.

Shaunfield S, Webster KA, Kaiser K, et al.

Neuroendocrinology 2021; (111(9)):850-862 doi:10.1159/000511482.

Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.

Eads JR, Reidy-Lagunes D, Soares HP, et al.

Pancreas 2020; (49(9)):1123-1130 doi:10.1097/MPA.0000000000001658.

Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management.

Jin C, Sharma AN, Thevakumar B, et al.

Cardiology 2021; (146(1)):65-73 doi:10.1159/000507847.

Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Ito T, Jensen RT

Expert opinion on pharmacotherapy 2021; (22(6)):685-693 doi:10.1080/14656566.2020.1845651.

Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors.

Artale S, Barzaghi S, Grillo N, et al.

Nutrition and cancer 2022; (74(1)):2-11 doi:10.1080/01635581.2020.1838572.

Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.

Tai E, Kennedy S, Farrell A, et al.

Current oncology (Toronto, Ont.) 2020; (27(6)):e537-e546 doi:10.3747/co.27.6205.

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors.

Gabrielsen J, Girone G, Bennett B, Jung A

Journal of the advanced practitioner in oncology 2019; (10(7)):646-659 doi:10.6004/jadpro.2019.10.7.2.

Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea.

Randall R, Bennett B, Valone T, Blue K

Journal of the advanced practitioner in oncology 2019; (10(8)):862-872 doi:10.6004/jadpro.2019.10.8.7.

Practical LC-MS/MS Method for 5-Hydroxyindoleacetic Acid in Urine.

Clark ZD, Cutler JM, Frank EL

The journal of applied laboratory medicine 2017; (1(4)):387-399 doi:10.1373/jalm.2016.021675.

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.

Strosberg JR, Srirajaskanthan R, El-Haddad G, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021; (62(12)):1712-1718 doi:10.2967/jnumed.120.258897.

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.

Zandee WT, Brabander T, Blažević A, et al.

The Journal of clinical endocrinology and metabolism 2021; (106(9)):e3665-e3672 doi:10.1210/clinem/dgab289.

Carcinoid heart disease of gonadal primary presenting with hypoxia: a case report.

O'Driscoll R, Prashar A, Youssef G, Sader M

European heart journal. Case reports 2021; (5(5)):ytaa536 doi:10.1093/ehjcr/ytaa536.

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Shah MH, Goldner WS, Benson AB, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(7)):839-868.

Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients.

Fijalkowski R, Reher D, Rinke A, et al.

Neuroendocrinology 2022; (112(6)):547-554 doi:10.1159/000518651.

Misleading clinical presentation of carcinoid syndrome.

Famerée L, Van Lier C, Borbath I, et al.

Acta gastro-enterologica Belgica 2021; (84(3)):501-503 doi:10.51821/84.3.016.

Progression of Carcinoid Heart Disease in the Modern Management Era.

Baron E, Szymanski C, Hergault H, et al.

Journal of the American Heart Association 2021; (10(23)):e020475 doi:10.1161/JAHA.120.020475.

Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force).

Hofland J, Lamarca A, Steeds R, et al.

Journal of neuroendocrinology 2022; (34(3)):e13060 doi:10.1111/jne.13060.

Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency.

Bardasi C, Benatti S, Luppi G, et al.

Cancers 2022; (14(3)) doi:10.3390/cancers14030662.

Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.

Maxwell JE, Naraev B, Halperin DM, et al.

Annals of surgical oncology 2022; (29(5)):3072-3084 doi:10.1245/s10434-022-11371-0.

Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

Holmager P, Langer SW, Kjaer A, et al.

Current treatment options in oncology 2022; (23(6)):806-817 doi:10.1007/s11864-022-00969-x.

Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis.

Xu A, Suz P, Reljic T, et al.

Cancers 2022; (14(12)) doi:10.3390/cancers14122966.

Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.

Koumarianou A, Daskalakis K, Tsoli M, et al.

Journal of neuroendocrinology 2022; (34(7)):e13174 doi:10.1111/jne.13174.

What do we know about carcinoid heart disease in the present era?

Pęczkowska M, Konsek-Komorowska SJ, Kolasińska-Ćwikła AD, et al.

Kardiologia polska 2022; (80(10)):990-1001 doi:10.33963/KP.a2022.0222.

A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease.

Mansour S, Anaka MR, Al-Agha R

The American journal of case reports 2022; (23()):e937403 doi:10.12659/AJCR.937403.

Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.

Gonzáles-Yovera JG, Roseboom PJ, Concepción-Zavaleta M, et al.

World journal of methodology 2022; (12(5)):381-391 doi:10.5662/wjm.v12.i5.381.

Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth in vivo.

Tow DH, Tran CG, Borbon LC, et al.

bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.04.07.536013.

Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.

Das S, Stockton SS, Hassan SA

The oncologist 2023; (28(7)):575-583 doi:10.1093/oncolo/oyad126.

The role of serotonin inhibition within the treatment of carcinoid syndrome.

George J, Ramage J, White B, Srirajaskanthan R

Endocrine oncology (Bristol, England) 2023; (3(1)):e220077 doi:10.1530/EO-22-0077.

The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease.

Johnson KKN, Stemann Lau T, Mark Dahl Baunwall S, et al.

Journal of neuroendocrinology 2023; (35(10)):e13327 doi:10.1111/jne.13327.

European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

Hofland J, Falconi M, Christ E, et al.

Journal of neuroendocrinology 2023; (35(8)):e13318 doi:10.1111/jne.13318.

Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.

Rossi RE, Lavezzi E, Jaafar S, et al.

Cancers 2023; (15(16)) doi:10.3390/cancers15164065.

The Role of Tryptophan Metabolism in the Occurrence and Progression of Acute and Chronic Kidney Diseases.

Hui Y, Zhao J, Yu Z, et al.

Molecular nutrition & food research 2023; (67(21)):e2300218 doi:10.1002/mnfr.202300218.

68 Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and/or Biochemical Suspicion of a Neuroendocrine Tumor.

Metser U, Ezzat S, Singh S, et al.

Clinical nuclear medicine 2023; (48(11)):933-936 doi:10.1097/RLU.0000000000004829.

What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators.

Mulders MCF, de Herder WW, Hofland J

Endocrine reviews 2024; (45(3)):351-360 doi:10.1210/endrev/bnad035.

Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy.

Rabei R, Fidelman N

Current treatment options in oncology 2023; (24(12)):1994-2004 doi:10.1007/s11864-023-01152-6.

Liver metastases of neuroendocrine tumors: Conventional transarterial chemoembolization and thermal ablation.

Vogl TJ, Gruber-Rouh T, Naguib NNN, et al.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2024; (196(4)):381-389 doi:10.1055/a-2193-0722.

Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.

Johansen SU, Hansen T, Nordborg A, et al.

Journal of neuroendocrinology 2024; (36(3)):e13372 doi:10.1111/jne.13372.

Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.

Saetiew K, Angkathunyakul N, Hunnangkul S, Pongpaibul A

Annals of diagnostic pathology 2024; (71()):152295 doi:10.1016/j.anndiagpath.2024.152295.

Managing end-stage carcinoid heart disease: A case report and literature review.

Bulj N, Tomasic V, Cigrovski Berkovic M

World journal of gastrointestinal oncology 2024; (16(3)):1076-1083 doi:10.4251/wjgo.v16.i3.1076.

[Current WHO classification (2022) of neuroendocrine neoplasms].

Buchstab O, Knösel T

Radiologie (Heidelberg, Germany) 2024; (64(7)):531-535 doi:10.1007/s00117-024-01295-z.

[Radiologically guided interventional therapies for the treatment of neuroendocrine tumors].

Radosa CG, Nebelung H, Schön F, Hoffmann RT

Radiologie (Heidelberg, Germany) 2024; (64(7)):575-581 doi:10.1007/s00117-024-01314-z.

Screening for carcinoid heart disease: Trends and future Perspectives.

Mouser B, Howe JR, Atari O, et al.

International journal of cardiology. Cardiovascular risk and prevention 2024; (22()):200293 doi:10.1016/j.ijcrp.2024.200293.

European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours.

Lamarca A, Bartsch DK, Caplin M, et al.

Journal of neuroendocrinology 2024; (36(9)):e13423 doi:10.1111/jne.13423.

Sarcopenia in Patients with Advanced Gastrointestinal Well-Differentiated Neuroendocrine Tumors.

Romano E, Polici M, Marasco M, et al.

Nutrients 2024; (16(14)) doi:10.3390/nu16142224.

Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment.

Sozio SJ, Raynor W, Becker MC, et al.

EJNMMI reports 2024; (8(1)):29 doi:10.1186/s41824-024-00216-6.

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers.

Algeri L, Falkman L, Spada F, et al.

ESMO open 2024; (9(11)):103959 doi:10.1016/j.esmoop.2024.103959.

Exploring Carcinoid Syndrome in Neuroendocrine Tumors: Insights from a Multidisciplinary Narrative Review.

Marasco M, Romano E, Arrivi G, et al.

Cancers 2024; (16(22)) doi:10.3390/cancers16223831.

The Value of Repeat 5-HIAA Measurements as a Predictor of Carcinoid Heart Disease: A Prospective 5-Year Follow-Up Study in Patients with Small Intestinal Neuroendocrine Tumors.

Kostiainen I, Simonen P, Aaltonen K, et al.

Cancers 2024; (16(23)) doi:10.3390/cancers16233896.

Fragility fractures in well-differentiated gastroenteropancreatic neuroendocrine tumors: Results from a multicentered retrospective study.

Brunetti A, Cellini M, Lavezzi E, et al.

Journal of neuroendocrinology 2025; (37(9)):e70053 doi:10.1111/jne.70053.

Atypical Presentation of Small Bowel Neuroendocrine Carcinoma Leading to Acute Obstruction.

Kumar A, Ramlakshmi V, Ahmad S, Antony AM

Cureus 2025; (17(5)):e84661 doi:10.7759/cureus.84661.

Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.

Massironi S, Gallo C, Franchina M, et al.

Expert review of gastroenterology & hepatology 2025; (19(10)):1119-1132 doi:10.1080/17474124.2025.2557245.

68Ga-DOTATATE PET/CT versus MRI in neuroendocrine liver metastases: a comprehensive per-lesion analysis.

Herold A, Hajati A, Cao Y, et al.

La Radiologia medica 2025; (130(11)):1742-1751 doi:10.1007/s11547-025-02080-1.

Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.

Chauhan A, Kizilgul M, Racila E, Zekarias K

Case reports in endocrinology 2026; (2026()):2260680 doi:10.1155/crie/2260680.

Primary Ovarian Neuroendocrine Neoplasm With Carcinoid Syndrome and Carcinoid Heart Disease.

Thammakosol K, Vathesatogkit P, Leelasithorn S, Sriphrapradang C

Ochsner journal 2026; (26(2)):173-178 doi:10.31486/toj.25.0101.

From Carcinoid Syndrome to Carcinoid Heart Disease: The Cost of Delayed Cardiac Surveillance.

Ballas CE, Tourmousoglou C, Arseniou A, Kolettis TM

Cureus 2026; (18(7)):e112770 doi:10.7759/cureus.112770.